Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which ripening method gets First-Time moms to vaginal delivery faster?

NCT ID NCT07717502

Disease control Sponsor: Ochsner Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This trial tests two ways to prepare the cervix for labor induction in first-time mothers with a single baby in head-down position at full term. One approach uses Dilapan-S dilators placed 12–24 hours before hospital admission, followed by misoprostol pills after removal. The other gives both treatments together after admission. The goal is to see which method helps more women deliver vaginally within 24 hours of entering the hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dilapan-S osmotic cervical dilators and misoprostol
What this could lead to
If successful, this could establish a more effective cervical ripening strategy to increase the chance of vaginal delivery within 24 hours for first-time mothers.
What could go wrong
This is a single-center trial with 260 participants, so results may not apply broadly. Both methods carry risks like uterine hyperstimulation or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Nulliparous patients with singleton pregnancies with vertex lie at term receiving prenatal care that are eligible for outpatient cervical ripening will be eligible Exclusion Criteria: * age less than 18, * suspected major fetal anomalies (including suspected or proven chromosome anomalies, congenital cardiac disease expected to require neonatal intervention, and multiple anomalies suggestive of a complex syndrome), * fetal growth restriction * oligohydramnios * prior full thickness * uterine scar * placenta previa, * low-lying placenta, * premature rupture of amniotic membranes, * cervical dilation \> 2 cm * modified Bishop score \> 4 * residence greater than 60 minutes from the hospital

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nulliparous women who scheduled for labor induction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nulliparous women who scheduled for labor induction Pregnancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ochsner Baptist

    RECRUITING

    New Orleans, Louisiana, 70115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.